Please assess the completion status of the following clinical trial:

Trial Title: Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma (a diagnostic biopsy with at least 10 cores is needed)~* Low and intermediate-risk NCCN risk categories: low-risk ( cT1-2a, Gleason Score ≤ 6 PSA \<10 ng/ml) and among those with intermediate-risk features (clinical stage T2b-c or GS 7 or PSA 10-20 ng/ml) those patients with favorable ones (a single factor for intermediate risk and GLS 3 + 4 and \<50% of biopsy cores containing cancer) will be selected. (30).~* Age ≥18 years~* Good performance status , Eastern Cooperative Oncology Group (ECOG) \< 2) or Karnofsky performance status (KPS) \> 70~* No previous pelvic RT~* Patient not eligible to prostatectomy or patient's refusal to undergo surgery.~* NO previous prostatectomy or TURP~* Good urinary flow (peak flow ≥ 10 ml/s)~* Previous ADT is permitted~* Prostate size ≤ 60 cc~* International Prostate Symptom Score ≤ 15~* Male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Nodal involvement or distant metastases (cN1 or cM1)~* Extracapsular tumor or locally advanced disease (cT3-cT4)~* IPSS questionnaire \> 20~* Concomitant inflammatory bowel~* Prior history of chronic prostatitis~* Prior history of urethral stricture~* Important systemic diseases or oral anticoagulant therapy ongoing~* Non-conformity to dose constraints at the treatment planning~* Other invasive cancer (apart from non-melanoma skin), unless the patient has been free from disease for at least 3 years;~* Abnormal complete blood count. Any of the following: platelet count less than 75,000/ml, Hb level less than 10 gm/dl, WBC less than 3.5/ml, abnormal renal function tests (creatinine \> 1.5), severe renal impairment (GFR less than 30)~* Placement of pacemakers and metallic vascular clips (all contraindication to performing prostate mpMRI).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose external beam Radiotherapy (Type: EXPERIMENTAL): Image-guided tomotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).